Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 152.
Bill is filed in its originating chamber and assigned a number.
Sponsor
Jim Banks (R-IN)
Filed in the Senate.
Next: In Committee
Members of the committee(s) the bill was referred to
Establishes user fees for over-the-counter drugs reviewed under FDA monograph process.
The problem
FDA needs funding to review and approve over-the-counter medications sold without prescriptions. Current system lacks dedicated revenue source for this regulatory work.
The proposal
Creates user fee program where companies pay FDA to review over-the-counter monograph drugs. Fees fund FDA staff and operations for drug safety review and approval.
The impact
Pharmaceutical companies pay fees. Consumers may see higher OTC drug prices. FDA gains resources to review drugs faster. Healthcare system gets better funded oversight.
Dedicated fees give FDA stable money to hire more reviewers and scientists. This speeds up approval of safe over-the-counter drugs. Better funding means faster, more thorough safety checks.
More FDA staff means companies get answers quicker on their drug applications. Consumers can access new over-the-counter medicines sooner. This reduces wait times in the approval process.
More resources let FDA conduct deeper reviews of drug safety. The agency can catch problems before drugs reach store shelves. This protects millions of Americans using over-the-counter medicines.
Companies using FDA services pay for them directly, not taxpayers. This follows common sense: those who benefit should share the cost. It avoids general budget drain.
Companies pass user fees to consumers as higher prices. Over-the-counter medicines cost more at drugstores. Low-income families buying cold medicine or pain relief pay more.
Large pharmaceutical companies absorb fees easily. Smaller companies and generics manufacturers struggle with these costs. This may reduce competition in over-the-counter market.
Bill summary is not yet public, so exact fee amounts are unknown. We cannot assess whether fees are reasonable or excessive. Consumers cannot judge true cost impact.
When regulated companies pay agency fees, conflicts of interest may arise. FDA might feel pressure to approve drugs faster to keep paying customers happy. This could compromise safety reviews.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.